|
|
|
 |
|
Clarient News Releases(RSS)
|
 |
Clarient to Present at Two Investor Conferences in September
ALISO VIEJO, Calif., Sept 07, 2010 /PRNewswire via COMTEX/ --Clarient, Inc. (Nasdaq: CLRT), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the biopharmaceutical industry, today announced that the Company is scheduled to make investor presentations at two investor conferences in the month of September.
Baird 2010 Health Care Conference at 2:15 p.m. EDT on Tuesday, September 14 in New York, NY. The conference will be held September 14-15 at the St. Regis Hotel.
UBS 2010 Global Life Sciences Conference at 11:00 a.m. EDT on Tuesday, September 21 in New York, NY. The conference will be held September 20-22 at the Grand Hy...
Clarient Announces U.S. and European Patents Allowed for Mammostrat(R) Breast Cancer Prognostic Test
Novel Test Classifies Risk of Recurrence of Breast Cancer
ALISO VIEJO, Calif., Aug 10, 2010 /PRNewswire via COMTEX/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that the United States Patent and Trademark Office and the European Patent Office have allowed patents covering the technology behind Clarient Insight(R) Dx Mammostrat(R), a test designed to aid in the classification of the risk of recurrence of breast cancer following surgery and initial treatment.
More than 210,000 women in the U.S. develop breast cancer each year. Mammostrat development was targeted to breast tumors...
Clarient to Present at Two Investor Conferences in August
ALISO VIEJO, Calif., Aug 04, 2010 /PRNewswire via COMTEX/ --Clarient, Inc. (Nasdaq: CLRT), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the biopharmaceutical industry, today announced that the Company is scheduled to make investor presentations at two investor conferences in the month of August.
Canaccord Genuity 30th Annual Growth Conference at 2:00 p.m. EDT on Tuesday, August 10 in Boston, MA. The conference will be held August 10-12 at the InterContinental Boston.
2010 Southern California Investor Conference at 9:00 a.m. PDT on Tuesday, August 17 at The Island Hotel in Newport Beach, CA.
A live webcast o...
Clarient Achieves Profitability and Continues Growth Trajectory in the Second Quarter of 2010
Net Revenue Increases 21%; Generates GAAP Profit and $2.5 Million Cash Flows from Operating Activities
ALISO VIEJO, Calif., July 28, 2010 /PRNewswire via COMTEX/ -- Clarient, Inc. (Nasdaq: CLRT), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the biopharmaceutical industry, today reported financial results for the second quarter ended June 30, 2010. Second quarter 2010 net revenue was $28.7 million, a 21 percent increase over the $23.7 million net revenue in the 2009 second quarter and a sequential increase of nearly eight percent over the $26.6 million in the first quarter of 2010.
Test volume in the 2010 second quarter increased...
Clarient to Announce 2010 Second Quarter and Six-Month Financial Results on Wednesday, July 28, 2010
Conference Call and Audio Webcast Scheduled for 5:00 p.m. EDT
ALISO VIEJO, Calif., July 20, 2010 /PRNewswire via COMTEX/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it will report its financial results for the second quarter and six months ended June 30, 2010 after the stock market closes on Wednesday, July 28.
Date: Wednesday, July 28, 2010
Start Time: 5:00 p.m. EDT
Call-in Number: 1-888-846-5003 (U.S.) / +1-480-629-9860 (International)
Conference ID Number: 4331129
Webcast: www.clarientinc.com/investor
Web Replay: For those unable to participate in the live br...
Clarient Announces Publication of Mammostrat(R) Breast Cancer Study in Breast Cancer Research
Novel Breast Cancer Test Classifies Risk of Recurrence of Breast Cancer
ALISO VIEJO, Calif., July 12, 2010 /PRNewswire via COMTEX/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that a manuscript based on a study of Clarient Insight(R)Dx Mammostrat(R), a test used to classify the risk of recurrence of breast cancer following surgery and chemotherapy, will be published in an upcoming edition of Breast Cancer Research, a prominent peer-reviewed medical journal. The manuscript, currently available in provisional format at the journal website (http://breast-cancer-research.com), is titl...
Clarient Names Neal S. Goldstein, M.D. Director of Surgical Pathology
Nationally Known Author, Thought Leader in Surgical, Molecular Pathology
ALISO VIEJO, Calif., June 16, 2010 /PRNewswire via COMTEX/ --Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that Neal S. Goldstein, M.D., has been named the Company's Director of Surgical Pathology. He reports directly to Chief Medical Officer Kenneth J. Bloom, M.D.
Dr. Goldstein is a nationally known surgical pathologist with expertise in molecular pathology, immunohistochemistry, gastrointestinal pathology and breast pathology. Dr. Goldstein was most recently Laboratory Director at Redford, MI-based Advance...
Clarient, Generation Health Sign Agreement to Provide, Manage Genetic Testing
Expands Potential Market for Clarient's Diagnostic Tests
ALISO VIEJO, Calif., June 10, 2010 /PRNewswire via COMTEX/ --Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced a new contractual agreement with Generation Health, Inc. (GH). This agreement makes Clarient a preferred genetic testing lab for GH, thereby ensuring reimbursement of diagnostic tests done for GH's nationwide network of payor clients and expanding Clarient's potential market. GH is a genetic benefit management company partially-owned by CVS Caremark, the nation's largest pharmacy healthcare provider.
GH and Clarient will ...
Clarient Receives Patents for Taxane Biomarker
TLE3 Biomarker Anchors Proprietary Product Line Indicating Which Cancer Patients Will Benefit from Important But Toxic Taxane Chemotherapy Regimen
ALISO VIEJO, Calif., June 8, 2010 /PRNewswire via COMTEX/ --Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that the United Kingdom Patent Office has granted a U.K. patent on the Company's TLE3 biomarker, a marker which may be used to predict which cancer patients will respond favorably to taxane therapy. In addition, the Company has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent on...
Clarient to Present at Three Investor Conferences in June
ALISO VIEJO, Calif., June 1, 2010 /PRNewswire via COMTEX/ --Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that the company is scheduled to make investor presentations at three investor conferences in the month of June.
Jefferies 2010 Global Life Sciences Conference at 1:00 p.m. EDT on Tuesday, June 8 in New York City. The conference will be held June 8-11.
Morgan Joseph 2010 Investor Conference at 4:00 p.m. EDT on Wednesday, June 9 in New York City. The conference will be held June 9 at the Millennium Broadway Hotel.
ThinkEquity Mid-Year Check-Up on Healthcare Conference at 1:30...
|
|
 |
|
|
|